Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE2
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant Treatment of Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2